{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T21:10:55Z","timestamp":1653340255822},"reference-count":39,"publisher":"Mark Allen Group","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Nurs"],"published-print":{"date-parts":[[2005,6,1]]},"abstract":"<jats:p> Gonorrhoea is currently the second most common bacterial sexually transmitted infection in England and Wales (Public Health Laboratory Service, 2002). Early initiation of treatment is important in the reduction of the onward transmission of infection and contributes to the overall control of the spread of gonorrhoea. A central tenet of this is the use of effective antimicrobial treatment. Both global and local surveillance programmes have successfully generated robust data, identifying the prevalence of antimicrobial resistance when using fluoroquinolones, formerly a first-line treatment for genital infection with Neisseria gonorrhoeae. As a result of this evidence base, the first-line treatment recommendations in England and Wales were changed. It is now recommended that anogenital gonorrhoea is treated with third generation cephalosporins, with either a 400mg single oral dose of cefixime, or a single intramuscular dose of ceftriaxone 250mg. This change in 2004 in first-line treatment exemplifies the application and delivery of evidence-based treatment and care. <\/jats:p>","DOI":"10.12968\/bjon.2005.14.12.18285","type":"journal-article","created":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T14:09:53Z","timestamp":1400854193000},"page":"646-652","source":"Crossref","is-referenced-by-count":2,"title":["Guidance for first-line treatment of anogenital gonorrhoea infection"],"prefix":"10.12968","volume":"14","author":[{"given":"Mandy","family":"Tyson","sequence":"first","affiliation":[{"name":"Department of Genitourinary Medicine,York Hospitals NHS Trust, Monkgate Health Centre, York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5130","reference":[{"key":"p_13","volume-title":"in","year":"1999"},{"key":"p_16","volume-title":"resulted from overwhelming evidence of","year":"2004"},{"key":"p_27","volume-title":"was commissioned by","author":"Moran","year":"1995"},{"key":"p_76","volume-title":"Clinical Effectiveness Group (2001) In England and Wales","author":"Source","year":"2003"},{"issue":"46","key":"p_95","first-page":"1041","volume":"51","author":"Anonymous","year":"2001","journal-title":"Morb Mortal Wkly Rep"},{"key":"p_96","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)92467-3"},{"key":"p_97","first-page":"315","volume":"72","author":"Bignell C","year":"1996","journal-title":"Genitourin Med"},{"key":"p_98","volume-title":"The 2003 Guidelines for the Management of Gonorrhoea in Adults (interim guidance)","author":"Bignell C","year":"2003"},{"issue":"6","key":"p_99","first-page":"987","volume":"47","author":"Castor D","year":"2001","journal-title":"Cell Mol Biol"},{"key":"p_100","first-page":"S13","volume":"75","author":"Clinical Effectiveness Group (The Association of Genitourinary Medicine and The Medical Society for the Study of Venereal Disease)","year":"1999","journal-title":"Sex Transm Infect"},{"key":"p_101","volume-title":"National Guidelines on the Management of Gonorrhoea in Adults (http:\/\/www.bashh. org\/guidelines\/2002\/gc_0601.pdf) (accessed","author":"Clinical Effectiveness Group (The Association of Genitourinary Medicine and The Medical Society for the Study of Venereal Disease)","year":"2001"},{"key":"p_102","volume-title":"National Guidelines on the Management of Gonorrhoea in Adults, (http:\/\/www.bashh.org\/guidelines\/ ceguidelines.htm) (accessed","author":"Clinical Effectiveness Group (The British Association for Sexual Health and HIV)","year":"2004"},{"issue":"4","key":"p_103","first-page":"541","volume":"26","author":"Communicable Diseases Intelligence","year":"2002","journal-title":"Commun Dis Intell"},{"key":"p_104","doi-asserted-by":"publisher","DOI":"10.1258\/095646203765371259"},{"key":"p_105","volume-title":"London","author":"Department of Health","year":"2000"},{"key":"p_106","volume-title":"London","author":"Department of Health","year":"2001"},{"key":"p_107","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200207000-00002"},{"key":"p_108","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199411000-00009"},{"key":"p_109","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13489-7"},{"key":"p_110","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(96)70263-9"},{"key":"p_111","volume-title":"Annual Report for Year 2001 Collection. The Public Health Laboratory Service","author":"Gonococcal Resistance","year":"2001"},{"key":"p_112","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-197904000-00018"},{"key":"p_113","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-197904000-00014"},{"issue":"2","key":"p_114","first-page":"115","volume":"27","author":"Guoming L","year":"2000","journal-title":"SexTransm Dis"},{"key":"p_115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111073251903"},{"issue":"4","key":"p_116","first-page":"253","volume":"72","author":"Ison CA","year":"1996","journal-title":"Genitourin Med"},{"key":"p_117","volume-title":"The Development of a European Surveillance Programme for Gonorrhoea","author":"Ison CA","year":"2003"},{"key":"p_118","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200301000-00003"},{"key":"p_119","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199501000-00007"},{"key":"p_120","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_6.S633"},{"key":"p_121","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/clinids\/20.Supplement_1.S47","volume":"20","author":"Moran JS","year":"1995","journal-title":"Clinical Infectious Diseases"},{"key":"p_122","volume-title":"Lancet ii: 657-8","author":"Phillips I","year":"1976"},{"key":"p_123","volume-title":"London","author":"Public Health Laboratory Service","year":"2000"},{"key":"p_124","volume-title":"DHSS and PS and the Scottish ISD","author":"Public Health Laboratory Service","year":"2002"},{"key":"p_125","doi-asserted-by":"publisher","DOI":"10.1258\/0956462001915471"},{"key":"p_126","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2001.117662"},{"key":"p_127","volume-title":"The Bacterial Special Interest Group Gonorrhoea Update Day. The Medical Socoiety for the Study ofVeneral Disease (MSSVD)","author":"Royal College of Physicians","year":"2003"},{"key":"p_128","volume-title":"Findings of the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP)","author":"Rudd E","year":"2003"},{"issue":"3","key":"p_129","first-page":"176","volume":"59","author":"Zajdowicz TR","year":"1983","journal-title":"Br JVen Dis"}],"container-title":["British Journal of Nursing"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/pdf\/10.12968\/bjon.2005.14.12.18285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T20:48:22Z","timestamp":1653338902000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/10.12968\/bjon.2005.14.12.18285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,6,1]]}},"alternative-id":["10.12968\/bjon.2005.14.12.18285"],"URL":"https:\/\/doi.org\/10.12968\/bjon.2005.14.12.18285","relation":{},"ISSN":["0966-0461","2052-2819"],"issn-type":[{"value":"0966-0461","type":"print"},{"value":"2052-2819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,1]]}}}